ACLX
HealthcareArcellx, Inc.
$61.83
$-1.51 (-2.38%)
Jan 5, 2026
Price History (1Y)
Analysis
Arcellx, Inc. is a biotechnology company in the healthcare sector with a market capitalization of $3.58 billion and 163 employees. The company's revenue over the trailing twelve months (TTM) was $35.90 million. The company's financial health indicates significant losses, with an EBITDA loss of $235.7 million and a net income loss of $217.9 million over the TTM period. This is reflected in its margins, with operating and profit margins both at 0.0% and -1248.3%, respectively. On the other hand, the company's cash position stands at $461.38 million, while its debt is $51.79 million. The current ratio of 3.99 suggests that Arcellx has sufficient liquidity to meet its short-term obligations. The valuation context for Arcellx is characterized by a forward P/E ratio of -18.89 and an EV/EBITDA of -13.80, indicating that investors are expecting significant growth or turnaround in the company's financial performance. The revenue growth over the year has been negative at -81.0%, while earnings growth data is not available.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Arcellx, Inc.
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; ARC-SparX programs in Phase 1 trials; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Visit website →Key Statistics
- Market Cap
- $3.58B
- P/E Ratio
- N/A
- 52-Week High
- $94.07
- 52-Week Low
- $47.86
- Avg Volume
- 900.49K
- Beta
- 0.35
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 163